Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP reduced its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 69.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,171 shares of the company's stock after selling 204,832 shares during the quarter. Two Sigma Investments LP owned about 0.24% of Tarsus Pharmaceuticals worth $5,048,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TARS. Crowley Wealth Management Inc. purchased a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth about $25,000. R Squared Ltd acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at about $53,000. Quarry LP purchased a new position in Tarsus Pharmaceuticals during the 4th quarter worth approximately $166,000. HighTower Advisors LLC acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth approximately $207,000. Finally, Summit Investment Advisors Inc. increased its position in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after buying an additional 244 shares during the period. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 3,084 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total transaction of $154,539.24. Following the sale, the general counsel now owns 51,712 shares in the company, valued at approximately $2,591,288.32. This trade represents a 5.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the completion of the sale, the chief executive officer now directly owns 824,106 shares of the company's stock, valued at $41,205,300. The trade was a 0.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock valued at $1,581,173 in the last 90 days. 8.25% of the stock is currently owned by insiders.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS traded down $0.50 during midday trading on Friday, reaching $42.94. The stock had a trading volume of 428,338 shares, compared to its average volume of 702,325. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.80 billion, a P/E ratio of -11.27 and a beta of 0.94. The firm has a fifty day simple moving average of $46.93 and a two-hundred day simple moving average of $48.96. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.05. The business had revenue of $78.34 million for the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. On average, equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Wall Street Analysts Forecast Growth

TARS has been the subject of several research analyst reports. Jefferies Financial Group increased their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target for the company in a research note on Tuesday, May 27th. Barclays lowered their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Finally, Guggenheim increased their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $66.17.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.